Metagenics, Inc. said today that its research on the efficacy of hops and acacia in treating metabolic syndrome and hypercholesterolemia was presented at a leading international scientific conference focused on natural products.
Metagenics has been awarded multiple patents for its discovery of the role of phytochemicals extracted from hops and acacia in modulating insulin signaling, a key mechanism in metabolic syndrome and hypercholesterolemia. “We were honored to have the opportunity to share our findings with the greater scientific community,” said Dr. Brian Carroll, who presented the research.
The 7th Joint Meeting of AFERP, ASP, GA, PSE & SIF Congress, which took place August 3-8 2008 in Athens, Greece, is an international consortium of pharmaceutical, nutraceutical, cosmetic, agrochemical researchers and industry representatives with an interest in natural products. The Meeting serves as a forum for the global scientific community and natural products industry to present new research and discuss current scientific trends. Among the topics presented and discussed were: health improvement through dietary phytochemicals, drug discovery from natural sources, new sources of bioactive natural products, bioavailability and quality of herbal therapeutics, and modern approaches to traditional medicines.
About Metagenics, Inc.
Metagenics is a life sciences company and leading developer and manufacturer of professional grade, science-based medical foods and nutraceuticals sold to healthcare practitioners worldwide. For more than 25 years, Metagenics has been a leader in quality, scientific discovery, and innovation, with multiple proprietary formula patents and more than 400 research-based products to optimize health. The company is headquartered in San Clemente, CA, with manufacturing and research facilities located in Gig Harbor, WA, including the MetaProteomics® Nutrigenomics Research Center and the Functional Medicine Research CenterSM for human clinical research. For more information, please visit www.metagenics.com.